Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate (Q38073207)

28 August 2017

1 reference

title

Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate (English)

1 reference

28 August 2017

0 references

Ashley M Newland

1

1 reference

28 August 2017

Jenny X Li

2

1 reference

28 August 2017

Lindsey E Wasco

3

1 reference

28 August 2017

May T Aziz

4

1 reference

28 August 2017

Denise K Lowe

5

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

33

1 reference

28 August 2017

1

1 reference

28 August 2017

93-104

1 reference

The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner

28 August 2017

1 reference

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

21 January 2018

1 reference

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

21 January 2018

1 reference

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant

21 January 2018

1 reference

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

21 January 2018

1 reference

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma

21 January 2018

1 reference

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

21 January 2018

1 reference

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

21 January 2018

1 reference

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

21 January 2018

1 reference

Anaplastic large cell lymphoma, ALK-positive

21 January 2018

1 reference

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

CD30-targeted antibody therapy

21 January 2018

1 reference

Brentuximab Vedotin (SGN-35).

21 January 2018

1 reference

Antibody conjugate therapeutics: challenges and potential

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

21 January 2018

1 reference

Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1170

1 reference

28 August 2017

1 reference